DOD Pancreatic Cancer, Idea Development Award | HT942524PCARPIDA

Opportunity Information: Apply for HT942524PCARPIDA

The DOD Pancreatic Cancer Research Program (PCARP) Idea Development Award (Funding Opportunity Number HT942524PCARPIDA) is a discretionary Department of the Army/USAMRAA grant opportunity intended to push pancreatic cancer research forward by backing bold, high-risk/high-reward ideas. The goal is to help researchers generate compelling, impactful data that can open up new lines of investigation and ultimately speed progress toward better outcomes for people affected by pancreatic cancer. This mechanism is built for projects that aim for major advances or critical discoveries rather than safe, incremental extensions of what is already well established.

A central theme of the award is impact. Applications are expected to clearly explain how the proposed work would make an important and original contribution to pancreatic cancer research and how it could plausibly translate, over time, into improvements in patient care or patient outcomes. Even if the project is not immediately clinical, the application should still make a persuasive case for why the work matters and how it could move the field in a meaningful way.

Innovation is another core requirement. Competitive proposals should either introduce a new paradigm, challenge prevailing assumptions, reframe existing problems from a fresh angle, or apply notably creative approaches. Innovation can come from the scientific concept itself, the methods and technologies used, or a novel adaptation of existing tools. The opportunity explicitly notes that research that is mainly incremental compared to previously published work is not considered innovative for this award, so applicants need to show what is genuinely new and why it could change what researchers know or can do.

The program also places strong emphasis on the research team. At least one person on the team must bring clear, recent experience in pancreatic cancer research, supported by publications and funding. This is meant to ensure that the project is grounded in real expertise in the disease area while still encouraging new ideas. The funding announcement also encourages including a biostatistician, reflecting the expectation that studies will be designed with strong analytical rigor and that data generation will be credible and interpretable.

While the award supports early-stage, idea-driven work, it is not meant for purely speculative proposals with no foundation. The research must be supported by preliminary data, although the preliminary evidence does not have to come directly from pancreatic cancer studies. Unpublished results are allowed, and data can come from the PI, the research team, or collaborators listed on the application. What matters is that the proposal connects that preliminary evidence to pancreatic cancer through a solid scientific rationale built from careful reasoning and a critical analysis of the literature, demonstrating that the idea is bold but still scientifically defensible.

A notable feature in FY24 is the Partnering PI option designed to help Early-Career Investigators enter and build a career in pancreatic cancer research. Under this option, an experienced investigator serves as the Initiating PI and mentor, partnering with an eligible Early-Career Investigator who serves as the Partnering PI. The intent is real mentorship and collaboration, not a nominal role: both PIs are expected to contribute substantially to the research plan and key application components such as the Project Narrative and Statement of Work. The Initiating PI handles most administrative aspects of submission, and if funded, each PI is named on an individual award within the recipient organization. The mechanism also encourages convergence science partnerships, signaling interest in cross-disciplinary collaborations that combine different fields, tools, and perspectives to tackle pancreatic cancer problems in new ways.

From an administrative standpoint, the opportunity is a grant in the Science and Technology/Research and Development category (CFDA 12.420), with eligibility listed as unrestricted. The original closing date is October 3, 2024, and the program anticipates making about 8 awards. The notice lists an award ceiling but does not provide a specific dollar amount in the supplied text, so applicants would need to confirm the maximum funding level in the full announcement materials.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Pancreatic Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-04-29.
• Applicants must submit their applications by 2024-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524PCARPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: